Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals promising developments: Arvinas is negotiating a collaboration with Pfizer for vepdeg, has a strong pipeline with significant clinical milestones expected, and has extended its cash runway to 2028. The Q&A highlights potential in the BCL6 and LRRK2 programs, and ARV-806's differentiation. Despite some unclear guidance, the company's strategic focus and financial health suggest a positive outlook, likely leading to a stock price increase of 2% to 8%.
Key Financial Performance
Cash, Cash Equivalents, and Marketable Securities $787.6 million as of September 30, 2025, compared to $1.04 billion as of December 31, 2024. The decrease was due to operational expenses and investments.
Revenue $41.9 million for Q3 2025, compared to $102.4 million for Q3 2024. The $60.5 million decrease was driven by the Novartis License Agreement, which had revenue recognized through the end of 2024, offset by a $20 million milestone payment from Novartis in Q3 2025.
General and Administrative Expenses $21 million for Q3 2025, compared to $75.8 million for Q3 2024. The $54.8 million decrease was primarily due to the termination of a lease, reduced personnel and infrastructure-related costs, and lower professional fees.
Research and Development Expenses $64.7 million for Q3 2025, compared to $86.9 million for Q3 2024. The $22.2 million decrease was driven by reduced spending on the vepdeg and luxdeg programs, and lower personnel expenses, offset by increased spending on the KRAS program.
Non-GAAP General and Administrative Expenses $14.6 million for Q3 2025, compared to $64.8 million for Q3 2024. The decrease aligns with overall reductions in administrative costs.
Non-GAAP Research and Development Expenses $56.9 million for Q3 2025, compared to $73.2 million for Q3 2024. The decrease reflects cost reductions in specific programs and personnel.
Stock Repurchase Approximately 2.56 million shares repurchased at an average price of $7.91 per share, as part of a $100 million stock repurchase authorization.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ARV-102: Clinical data from ARV-102, a LRRK2 degrader, showed it is well-tolerated in Phase I trials for Parkinson's disease and healthy volunteers. It demonstrated significant reductions in LRRK2 protein and biomarkers, suggesting potential best-in-class impact on disease processes.
ARV-806: Preclinical data for ARV-806, a KRAS G12D degrader, showed high potency and differentiation from existing therapies. It demonstrated robust antitumor activity and durable degradation in models of pancreatic, colorectal, and lung cancers.
ARV-393: ARV-393, a BCL6 degrader, showed early responses in Phase I trials for B- and T-cell lymphomas, even at sub-efficacious exposure levels. Preclinical data also highlighted its potential in combination therapies for aggressive lymphomas.
ARV-027: Preclinical data for ARV-027, targeting polyQ-AR for spinal bulbar muscular atrophy, showed promise as a treatment for this rare neuromuscular disease.
ARV-6723: ARV-6723, targeting HPK1 for immuno-oncology, showed preclinical promise in addressing tumor microenvironment immune suppression.
Vepdegestrant commercialization: Arvinas and Pfizer plan to select a third party for the commercialization of vepdegestrant, targeting ER-positive/HER2-negative advanced breast cancer. The FDA's PDUFA action date is June 5, 2026.
Cost reductions: Arvinas implemented cost reduction measures, including a quarterly run rate spend below $75 million and a stock repurchase program, to maintain financial flexibility and extend cash runway into the second half of 2028.
Pipeline focus: Arvinas is focusing on advancing its neuroscience and oncology pipeline, with multiple study initiations and data readouts planned for 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Uncertainty: The new drug application for vepdegestrant is under review by the FDA with a PDUFA action date of June 5, 2026. There is uncertainty regarding the approval process and the need to have a commercialization partner in place before this date.
Financial Sustainability: The company reported a significant decrease in revenue compared to the previous year, driven by the conclusion of a major licensing agreement. While cost reductions have been implemented, the company is still reliant on its cash reserves, which are projected to last until the second half of 2028.
Pipeline Development Risks: The company is heavily reliant on its pipeline of clinical and preclinical programs, which are in various stages of development. Delays or failures in clinical trials, such as the ongoing Phase I trials for ARV-102 and ARV-393, could adversely impact the company's strategic objectives.
Market Competition: The company is developing therapies for highly competitive areas such as oncology and neurology. The success of its products depends on differentiation from existing therapies and competitors' advancements.
Operational Efficiency: The company has implemented cost reduction programs and reduced its workforce, which could impact operational efficiency and the ability to execute its strategic plans effectively.
Commercialization Challenges: The company and Pfizer are seeking a third-party partner for the commercialization of vepdegestrant. Delays in securing a partner could impact the product's market readiness and potential revenue generation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Financial Guidance: The company has cash on hand to sustain operations into the second half of 2028. Non-GAAP expenses are expected to remain below $300 million in fiscal year 2026, with a quarterly run rate spend below $75 million. The company has authorized a $100 million stock repurchase program, with 2.56 million shares already repurchased at an average price of $7.91 per share.
Pipeline and Clinical Development: The company plans to initiate a Phase Ib trial for ARV-102 in patients with progressive supranuclear palsy (PSP) in the first half of 2026. Data from the multiple dose cohort of the Parkinson's disease trial for ARV-102, including CSF LRRK2 degradation data, will be shared at a medical conference in 2026. A combination trial for ARV-393 with glofitamab in diffuse large B-cell lymphoma (DLBCL) is planned for 2026. Initial clinical data for ARV-806, targeting KRAS G12D, will be shared in 2026. First-in-human studies for ARV-027 and ARV-6723 are anticipated to begin in 2026.
Regulatory Milestones: The FDA has set a PDUFA action date of June 5, 2026, for the new drug application of vepdegestrant. The company aims to have a commercialization partner in place before this date to ensure launch readiness.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Authorization: In September, the Board authorized the repurchase of up to $100 million of outstanding common stock. This decision reflects the Board's confidence in the company's long-term strategy and belief that the current share price is undervalued relative to its long-term opportunity.
Repurchase Progress: As of the end of September, approximately 2.56 million shares have been repurchased at an average share price of $7.91 per share.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you comment on the points of differentiation for the BCL6 degrader program and its dosing profile?
A:The BCL6 degrader is dosed once daily as an oral drug. Differentiation includes achieving complete responses in various models versus tumor growth inhibition seen with competitors. The program focuses on monotherapy for AITL and combinations with bispecifics for DLBCL. It has shown monotherapy activity in T-cell and B-cell malignancies, which competitors have not reported.
Q:What are the first signals you are looking for in the LRRK2 program for Parkinson's disease MAD Phase I?
A:The study involves 28 days of dosing, primarily generating biomarker-related data with potential early clinical efficacy data. The drug has shown pathway engagement in healthy volunteers, impacting endolysosomal trafficking and neuroinflammation. The goal is to replicate these effects in Parkinson's patients and provide updates on pathway markers early next year.
Q:Do you have plans to test ARV-806 or a pan-KRAS degrader in a KRAS amplified population?
A:ARV-806 has been studied in resistant settings, showing durable KRAS repression. The pan-KRAS degrader has shown tumor growth inhibition and regression in wild-type amplified settings. The ongoing Phase I study excludes patients previously treated with KRAS inhibitors, but future updates may expand targeting to KRAS amplified populations.
Q:What are your expectations for ARV-102 MAD data in 2026?
A:The company will provide LRRK2 degradation data upon completing the MAD study in Parkinson's disease patients. They aim to achieve significant degradation levels and will guide further updates next year.
Q:Are there molecular features in ARV-806 that avoid GI tolerability and elevated liver enzymes seen with other G12D inhibitors?
A:ARV-806 binds to both on- and off-states and is 25x more potent than current mechanisms. It engages the target at lower concentrations, potentially avoiding toxicities like transaminitis seen in competitors. The goal is to achieve over 80% target degradation.
Q:Are you evaluating how PROTAC-mediated KRAS G12D degradation complements combination strategies like cetuximab pairing?
A:Preclinical evaluations show that ARV-806 combines well with anti-EGFR inhibitors like cetuximab. The selective approach to degrading G12D KRAS avoids challenges seen with pan-KRAS mechanisms. The company plans to share preclinical data within the year.
Q:What combination partners are most exciting for the BCL6 asset, and where does it fit in the lymphoma treatment paradigm?
A:BCL6 combines well with EZH2 inhibitors, BTK inhibitors, BCL2 inhibitors, and anti-CD20 agents. The focus is on combining with bispecifics targeting CD20 in second- and third-line settings for large B-cell lymphoma. Phase I studies with bispecific combinations are planned for next year.
Q:What is your BD strategy and approach to resource allocation given your pipeline and cash runway?
A:The company has reset its focus on its pipeline, including KRAS G12D, LRRK2, and BCL6, with two additional programs in SDMA and HPK1. They are open to selective partnering and have sufficient cash to fund early-phase studies. Decisions on keeping or licensing programs will be made as they progress.
Q:How do you think about the translatability of ARV-102 biomarker data into clinical endpoints for Parkinson's disease?
A:Biomarkers like GPNMB, IBA1, and CD68 are predictive of disease progression. ARV-102 has shown reductions in these biomarkers in healthy volunteers. The Parkinson's study aims to replicate these results, and a PSP study is planned for next year to further validate the approach.
Q:Do you have plans to explore other CAG repeat-related diseases beyond spinal cerebellar atrophy for ARV-027?
A:ARV-027 targets polyglutamine repeat androgen receptors and has shown promising results in SBMA. The company is also exploring selective ligands for mutant Huntington's disease and other repeat expansion disorders, though these efforts are in early stages.
Q:How early could we see combination cohorts for the KRAS program, and when will more data on HPK1 be available?
A:Combination cohorts for KRAS could start as early as next year, depending on clinical data. Preclinical data for HPK1 will be presented at SITC, showcasing its impact on T-cell exhaustion and the tumor microenvironment.
Q:What have you learned about drug-drug interactions with vepdeg, and how does this apply to new degraders?
A:PROTACs are analyzed for drug-drug interactions similarly to small molecules. Each PROTAC is unique, and potential interactions depend on individual compound properties.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on the timing of combination cohorts for the KRAS program, stating it would depend on clinical data. They also did not provide detailed expectations for ARV-102 MAD data in 2026, only stating they would guide updates next year.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARV LRRK
Arvinas
BCL degradation
CD
HPK
Investor Media
LRRK degradation
LRRK degrader
LRRK protein
MDS
PBMCs
PSP
Phase monotherapy
SITC
androgen receptor
antitumor activity
area need
atrophy SBMA
biomarkers patient
bulbar atrophy
concentration
creation
date
decrease
degrader ARV
dos milligram
exposure level
milligram dose
polyQ AR
protein function
receptor polyQ
reduction
repurchase
share price
study dos
track record
value
ARVN Transcript
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call summary indicates a mixed financial performance with a 12% increase in revenue and a 10% improvement in net loss, but a 15% decrease in cash reserves. The lack of strategic and risk discussions, combined with no clear guidance or new partnerships, suggests limited immediate catalysts for stock movement. Given the company's market cap, the overall sentiment is neutral, with potential for minor fluctuations based on investor interpretation of financial health and R&D investments.
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript
Positive2-24
The company shows strong financial health with a substantial stock repurchase program, promising product development with multiple trials and a potential FDA approval, and a strategic plan for commercialization. While there are some uncertainties in timelines and regulatory feedback, the overall outlook is optimistic. The market cap suggests moderate volatility, but the positive developments, particularly in clinical trials and regulatory milestones, are likely to outweigh the uncertainties, resulting in a positive stock price movement.
Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call reveals promising developments: Arvinas is negotiating a collaboration with Pfizer for vepdeg, has a strong pipeline with significant clinical milestones expected, and has extended its cash runway to 2028. The Q&A highlights potential in the BCL6 and LRRK2 programs, and ARV-806's differentiation. Despite some unclear guidance, the company's strategic focus and financial health suggest a positive outlook, likely leading to a stock price increase of 2% to 8%.
ARVN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
